Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Aver

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 […]

Related Keywords

China , Jeremy Bender , Piper Sandler , China Universal Asset Management Co , Day One Biopharmaceuticals Inc , Needham Company , Jpmorgan Chase Co , Nasdaq , Quintet Private Bank Europe , Exchange Traded Concepts , Goldman Sachs Group , Quest Partners , Day One Biopharmaceuticals , Get Free Report , Marketbeat Ratings , Universal Asset Management , Traded Concepts , One Biopharmaceuticals , Get Free , Day One Biopharmaceuticals Daily ,